Monthly archive | PharmaTutor

8 July 2016

Walk in interview for QC, QA, Production, Engineering at USV Limited

USV is aleading healthcare company with the following areas of focus: Generics, Active Pharmaceutical Ingredients (APIs) and Biosimilars. 68% of our business is contributed by India Operations and the rest by export of APIs and Generics. USV is a 48 year old healthcare company which began as a joint venture with USV&P Inc, a subsidiary of Revlon. Product range consists of Generics, Active Pharmaceutical Ingredients and Biotherapeutics that are manufactured in our modern cGMP compliant plants located in India.

Post : Officers/Sr. Officers

8 July 2016

Walk in interview in R&D, API, Production, QA, QC at Sun Pharma

With global revenues of over US$ 4.5 billion, Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide. Sun Pharma is also India’s largest and most trusted pharmaceutical company. Our global presence is supported by 45 manufacturing facilities across 5 continents.

Post : Sr.Officer/Executive/Sr.Executive

8 July 2016

A COMPARATIVE STUDYOF CENTRAL ANALGESIC ACTIVITY OF POTENTIAL ANTIDEPRESSANTS

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
S. VISWANTH REDDY*, G.AVINASH1, R. SAGAR2
PNR College of Pharmacy,
Shadnagar, Mahaboob Nagar (Dist), Telangana
vishwanth555@gmail.com

ABSTRACT
Pain is an ill defined, disabling accompaniment of many medical conditions. It is often evoked by an external and internal noxious stimulus. It affects millions of people suffering with depression and other psychiatric disorders. Most of the antidepressants are having analgesic capacity to treat the pain by inhibiting nociceptive stimuli by increasing the seratonergic and noradrenergic transmission in CNS.

Objectives
The Present study carried out to investigate the central analgesic activity of potential antidepressants like Fluoxetine, Imipramine, Amitriptyline and to compare the analgesic activity with standard central analgesic Pentazocine.

Methods
Analgesic activity was evaluated by using hot plate and tail immersion models in mice. Fluoxetine (10 mg/kg), Imipramine (20 mg/kg), Amitriptyline(20 mg/kg) were used as test drugs and Pentazocine (10 mg/kg) was used as standard drug.

Results
In tail immersion model of analgesic activity Fluoxetine possess significant analgesic activity (*p<0.05 at 60 min interval, ***p<0.001 at 90 and 120 min interval) Amitriptyline also showed significant analgesic activity (**p<0.01) at 90 min interval and ***p<0.001 at 120 min interval. Imipramine is the least effective analgesic in this study showed mild analgesic activity (*p<0.05 at 90 min interval and **p <0.01 at 120 min interval).

In hot plate analgesic model Fluoxetine and Amitriptyline possess significant analgesic activity (***p<0.001 at 120 min interval), Imipramine same like above said model less effective, doesn’t shown significant analgesic activity.

Conclusion
All the test drugs significantly reduce the painful stimuli when compared to the control group in both the models. These results suggest that the antidepressants which increase the monoamine transmission in the brain posse’s significant antidepressant activity and might be useful as potent analgesics.

Read more about Claris Lifesciences receive ANDA nod for Tobramycin Injection

Claris Lifesciences Ltd has announced that it has received the abbreviated new drug application (ANDA) approval for Tobramycin injection USP, 80mg/2mL and 1200 mg/30mL multiple dose vials, in the United States of America.

Read more about Otsuka Pharma subsidiary Interpharma Praha launch ORALTAG in U.S.

Otsuka Pharmaceutical Co. Ltd. and its wholly-owned subsidiary Interpharma Praha, a.s. announced that ORALTAG, a formulation of dry, dissolvable iohexol powder for oral solution, will become commercially available from WMB Enterprises, LLC, (a wholly owned subsidiary of Beekley Corporation) and marketed by Beekley Medical.

Revive Therapeutics Ltd announced that the U.S. Food and Drug Administration ("US FDA") has accepted the Company's Investigational New Drug Application ("IND") for a Phase 2 clinical study in the U.S. of Bucillamine for the treatment of cystinuria.

"I am very pleased to have received FDA acceptance of Revive's second IND to support the clinical evaluation of Bucillamine as a potential new treatment for cystinuria," said Fabio Chianelli, President of Revive. "This marks another significant milestone for Revive and we look forward to initiating this Phase 2 study shortly."

Cystinuria is a rare autosomal recessive genetic disorder that causes high levels of cystine in the urine thus causing kidney stones to form. The resulting kidney stones are often large and recurrent and lead to significant morbidity and sometimes loss of kidney function. There are approximately between 10,000 and 12,000 patients affected with cystinuria in the U.S. The worldwide prevalence is about 1 in 7,000.

Current drugs approved by the US FDA for the treatment of cystinuria include Cuprimine® (D-penicillamine), which is a registered trademark of Valeant Pharmaceuticals International, Inc. and Thiola® (Tiopronin), which is marketed by Retrophin, Inc. Both patent protection and the seven-year period of marketing exclusivity from the orphan drug designation for Cuprimine® and Thiola® have expired. Since the approval of Thiola® in 1988, there have been no significant improvements in the treatment of cystinuria. Revive is repurposing Bucillamine as a potential new treatment in cystinuria.

Bucillamine is an oral small molecule drug prescribed for rheumatoid arthritis in Japan and South Korea for nearly 30 years. Bucillamine has a chemical structure similar to Thiola®, but has two active thiol groups versus only one for Thiola®. The Company received US FDA orphan designation status for the use of Bucillamine for the treatment of cystinuria.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email

Read more about Sandoz EGALITY trial result of biosimilar etanercept show equivalent efficacy to originator product

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. The study was presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network (PIN), Paris, France.

7 July 2016

Career as Technical Editor-Scientific Writing at Innovational Publishers

Innovational Publishers are publishers and scientific services provider and having peer-reviewed open access journals. These free-to-view online journals cover all major disciplines of science and medicine.

Post: Technical Editor-Scientific Writing

7 July 2016

Opportunity for Compounder(Pharmacist)/ Compounder in Plantation Corporation of Kerala Limited - 3 posts

The Kerala Public Service Commission is a body created by the Constitution of India.

7 July 2016

Kalaniketan Polytechnic College, Jabalpur hiring Guest Faculty (Pharmacy)

Kalaniketan Polytechnic College, Jabalpur is hiring Guest Faculty (Pharmacy) for its office based in Madhya Pradesh. Selected person will teach the under graduate students in the concern discipline. Candidates with requisite medical qualifications may apply on or before 18 July 2016.

Kalaniketan Polytechnic College, Jabalpur Guest Faculty (Pharmacy) Vacancy 2016 Details